Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Jones P, Kafonek S, Laurora I, Hunninghake D (March 1998). "Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)". The American Journal of Cardiology. 81 (5): 582–7. doi:10.1016/S0002-9149(97)00965-X. PMID9514454.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. (2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". Lancet. 364 (9435): 685–96. doi:10.1016/S0140-6736(04)16895-5. PMID15325833. S2CID28885209.
Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al. (December 2000). "Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia". Diabetes, Obesity & Metabolism. 2 (6): 355–62. doi:10.1046/j.1463-1326.2000.00106.x. PMID11225965. S2CID27148191.
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. (December 2011). "Effect of two intensive statin regimens on progression of coronary disease". The New England Journal of Medicine. 365 (22): 2078–87. doi:10.1056/NEJMoa1110874. PMID22085316.
Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H (June 2016). "Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis". American Journal of Kidney Diseases. 67 (6): 881–892. doi:10.1053/j.ajkd.2016.01.016. PMID26905361.
Geng Q, Ren J, Song J, Li S, Chen H (August 2014). "Meta-analysis of the effect of statins on renal function". The American Journal of Cardiology. 114 (4): 562–570. doi:10.1016/j.amjcard.2014.05.033. PMID25001155.
Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, et al. (October 2014). "Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial". Stroke. 45 (10): 2974–2982. doi:10.1161/STROKEAHA.114.005832. PMID25147328. S2CID6575836.
Xiong B, Nie D, Cao Y, Zou Y, Yao Y, Qian J, et al. (November 2017). "Preoperative Statin Treatment for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomised Controlled Trials". Heart, Lung & Circulation. 26 (11): 1200–1207. doi:10.1016/j.hlc.2016.11.024. PMID28242291.
Zhou X, Dai J, Xu X, Wang Z, Xu H, Chen J, et al. (April 2019). "Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis". Angiology. 70 (4): 305–316. doi:10.1177/0003319718801246. PMID30261736. S2CID52875826.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. (November 2005). "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial". Lancet. 366 (9500): 1849–1861. doi:10.1016/S0140-6736(05)67667-2. PMID16310551. S2CID40744740.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E (July 2005). "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis". The New England Journal of Medicine. 353 (3): 238–48. doi:10.1056/NEJMoa043545. PMID16034009.
Thakker D, Nair S, Pagada A, Jamdade V, Malik A (October 2016). "Statin use and the risk of developing diabetes: a network meta-analysis". Pharmacoepidemiology and Drug Safety. Wiley. 25 (10): 1131–1149. doi:10.1002/pds.4020. PMID27277934. S2CID22626629.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. Elsevier BV. 375 (9716): 735–742. doi:10.1016/s0140-6736(09)61965-6. PMID20167359. S2CID11544414.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Newman CB, Palmer G, Silbershatz H, Szarek M (September 2003). "Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients". American Journal of Cardiology. 92 (6): 670–6. doi:10.1016/S0002-9149(03)00820-8. PMID12972104.
Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (September 2010). "Do statins beneficially or adversely affect glucose homeostasis?". Current Vascular Pharmacology. 8 (5): 612–31. doi:10.2174/157016110792006879. PMID20507274. S2CID220905587.
Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, et al. (August 2012). "Lipid-modifying therapies and risk of pancreatitis: a meta-analysis". JAMA. 308 (8): 804–811. doi:10.1001/jama.2012.8439. PMID22910758.
Kostis JB, Dobrzynski JM (July 2014). "The effect of statins on erectile dysfunction: a meta-analysis of randomized trials". The Journal of Sexual Medicine. 11 (7): 1626–35. doi:10.1111/jsm.12521. PMID24684744.
Cui Y, Zong H, Yan H, Zhang Y (June 2014). "The effect of statins on erectile dysfunction: a systematic review and meta-analysis". The Journal of Sexual Medicine. 11 (6): 1367–75. doi:10.1111/jsm.12497. PMID24628781.
Liberale L, Carbone F, Montecucco F, Sahebkar A (May 2020). "Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms". The International Journal of Biochemistry & Cell Biology. 122: 105735. doi:10.1016/j.biocel.2020.105735. PMID32126319. S2CID212408322.
Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. (August 2006). "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 355 (6): 549–559. doi:10.1056/NEJMoa061894. PMID16899775.
Roth BD, Blankley CJ, Chucholowski AW, Ferguson E, Hoefle ML, Ortwine DF, Newton RS, Sekerke CS, Sliskovic DR, Wilson M (1991). "Inhibitors of Cholesterol Biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one Inhibitors of HMG-CoA Reductase. 2. Effects of Introducing Substituents at Positions Three and Four of the Pyrrole Nucleus". J. Med. Chem.34 (1): 357–366. doi:10.1021/jm00105a056. PMID1992137.
Scandinavian Simvastatin Survival Study Group (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–9. doi:10.1016/s0140-6736(94)90566-5. PMID7968073. S2CID5965882.
US patent 4681893, Roth Bruce D., "Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis", issued 21 July 1987
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Jones P, Kafonek S, Laurora I, Hunninghake D (March 1998). "Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)". The American Journal of Cardiology. 81 (5): 582–7. doi:10.1016/S0002-9149(97)00965-X. PMID9514454.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. (2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". Lancet. 364 (9435): 685–96. doi:10.1016/S0140-6736(04)16895-5. PMID15325833. S2CID28885209.
Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al. (December 2000). "Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia". Diabetes, Obesity & Metabolism. 2 (6): 355–62. doi:10.1046/j.1463-1326.2000.00106.x. PMID11225965. S2CID27148191.
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. (December 2011). "Effect of two intensive statin regimens on progression of coronary disease". The New England Journal of Medicine. 365 (22): 2078–87. doi:10.1056/NEJMoa1110874. PMID22085316.
Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H (June 2016). "Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis". American Journal of Kidney Diseases. 67 (6): 881–892. doi:10.1053/j.ajkd.2016.01.016. PMID26905361.
Geng Q, Ren J, Song J, Li S, Chen H (August 2014). "Meta-analysis of the effect of statins on renal function". The American Journal of Cardiology. 114 (4): 562–570. doi:10.1016/j.amjcard.2014.05.033. PMID25001155.
Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, et al. (October 2014). "Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial". Stroke. 45 (10): 2974–2982. doi:10.1161/STROKEAHA.114.005832. PMID25147328. S2CID6575836.
Xiong B, Nie D, Cao Y, Zou Y, Yao Y, Qian J, et al. (November 2017). "Preoperative Statin Treatment for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomised Controlled Trials". Heart, Lung & Circulation. 26 (11): 1200–1207. doi:10.1016/j.hlc.2016.11.024. PMID28242291.
Zhou X, Dai J, Xu X, Wang Z, Xu H, Chen J, et al. (April 2019). "Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis". Angiology. 70 (4): 305–316. doi:10.1177/0003319718801246. PMID30261736. S2CID52875826.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. (November 2005). "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial". Lancet. 366 (9500): 1849–1861. doi:10.1016/S0140-6736(05)67667-2. PMID16310551. S2CID40744740.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E (July 2005). "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis". The New England Journal of Medicine. 353 (3): 238–48. doi:10.1056/NEJMoa043545. PMID16034009.
Thakker D, Nair S, Pagada A, Jamdade V, Malik A (October 2016). "Statin use and the risk of developing diabetes: a network meta-analysis". Pharmacoepidemiology and Drug Safety. Wiley. 25 (10): 1131–1149. doi:10.1002/pds.4020. PMID27277934. S2CID22626629.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. Elsevier BV. 375 (9716): 735–742. doi:10.1016/s0140-6736(09)61965-6. PMID20167359. S2CID11544414.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Newman CB, Palmer G, Silbershatz H, Szarek M (September 2003). "Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients". American Journal of Cardiology. 92 (6): 670–6. doi:10.1016/S0002-9149(03)00820-8. PMID12972104.
Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (September 2010). "Do statins beneficially or adversely affect glucose homeostasis?". Current Vascular Pharmacology. 8 (5): 612–31. doi:10.2174/157016110792006879. PMID20507274. S2CID220905587.
Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, et al. (August 2012). "Lipid-modifying therapies and risk of pancreatitis: a meta-analysis". JAMA. 308 (8): 804–811. doi:10.1001/jama.2012.8439. PMID22910758.
Kostis JB, Dobrzynski JM (July 2014). "The effect of statins on erectile dysfunction: a meta-analysis of randomized trials". The Journal of Sexual Medicine. 11 (7): 1626–35. doi:10.1111/jsm.12521. PMID24684744.
Cui Y, Zong H, Yan H, Zhang Y (June 2014). "The effect of statins on erectile dysfunction: a systematic review and meta-analysis". The Journal of Sexual Medicine. 11 (6): 1367–75. doi:10.1111/jsm.12497. PMID24628781.
Liberale L, Carbone F, Montecucco F, Sahebkar A (May 2020). "Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms". The International Journal of Biochemistry & Cell Biology. 122: 105735. doi:10.1016/j.biocel.2020.105735. PMID32126319. S2CID212408322.
Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. (August 2006). "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 355 (6): 549–559. doi:10.1056/NEJMoa061894. PMID16899775.
Roth BD, Blankley CJ, Chucholowski AW, Ferguson E, Hoefle ML, Ortwine DF, Newton RS, Sekerke CS, Sliskovic DR, Wilson M (1991). "Inhibitors of Cholesterol Biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one Inhibitors of HMG-CoA Reductase. 2. Effects of Introducing Substituents at Positions Three and Four of the Pyrrole Nucleus". J. Med. Chem.34 (1): 357–366. doi:10.1021/jm00105a056. PMID1992137.
Scandinavian Simvastatin Survival Study Group (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–9. doi:10.1016/s0140-6736(94)90566-5. PMID7968073. S2CID5965882.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. (2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". Lancet. 364 (9435): 685–96. doi:10.1016/S0140-6736(04)16895-5. PMID15325833. S2CID28885209.
Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al. (December 2000). "Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia". Diabetes, Obesity & Metabolism. 2 (6): 355–62. doi:10.1046/j.1463-1326.2000.00106.x. PMID11225965. S2CID27148191.
Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, et al. (October 2014). "Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial". Stroke. 45 (10): 2974–2982. doi:10.1161/STROKEAHA.114.005832. PMID25147328. S2CID6575836.
Zhou X, Dai J, Xu X, Wang Z, Xu H, Chen J, et al. (April 2019). "Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis". Angiology. 70 (4): 305–316. doi:10.1177/0003319718801246. PMID30261736. S2CID52875826.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. (November 2005). "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial". Lancet. 366 (9500): 1849–1861. doi:10.1016/S0140-6736(05)67667-2. PMID16310551. S2CID40744740.
Thakker D, Nair S, Pagada A, Jamdade V, Malik A (October 2016). "Statin use and the risk of developing diabetes: a network meta-analysis". Pharmacoepidemiology and Drug Safety. Wiley. 25 (10): 1131–1149. doi:10.1002/pds.4020. PMID27277934. S2CID22626629.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. Elsevier BV. 375 (9716): 735–742. doi:10.1016/s0140-6736(09)61965-6. PMID20167359. S2CID11544414.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID12686036. S2CID9409142.
Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (September 2010). "Do statins beneficially or adversely affect glucose homeostasis?". Current Vascular Pharmacology. 8 (5): 612–31. doi:10.2174/157016110792006879. PMID20507274. S2CID220905587.
Liberale L, Carbone F, Montecucco F, Sahebkar A (May 2020). "Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms". The International Journal of Biochemistry & Cell Biology. 122: 105735. doi:10.1016/j.biocel.2020.105735. PMID32126319. S2CID212408322.
Scandinavian Simvastatin Survival Study Group (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–9. doi:10.1016/s0140-6736(94)90566-5. PMID7968073. S2CID5965882.